Abstract:Background: With a 5% improvement in 5-year overall survival achieved with current neoadjuvant or adjuvant chemotherapy, new treatments for resectable non-small cell lung cancer (NSCLC) are urgently needed. The use of immune checkpoint inhibitors (ICIs) is established in metastatic NSCLC and is being evaluated in resectable NSCLC. Methods: Publications and conference databases and clinicaltrials.gov were searched for reports on clinical studies of neoadjuvant immunotherapy in patients with early resectable NSCLC. Results: Potential advantages of neoadjuvant ICIs include the following: earlier treatment of micrometastatic disease; activation of a broader, potentially durable immune response by the whole tumor and associated lymph nodes; and pathologic assessment of neoadjuvant treatment response, which may guide adjuvant therapy. Surgical considerations include delays to surgery, potential disease progression preventing curative resection, and perioperative morbidity and mortality. Surrogate end points of efficacy (pathologic complete response, major pathologic response) and biomarkers predictive of outcome (programmed death ligand 1 expression, tumor mutational burden, and circulating tumor DNA) can accelerate clinical trial completion and early-stage treatment development; their application in neoadjuvant ICI studies in NSCLC is reviewed. Conclusions: Phase 2 trials of neoadjuvant ICIs alone or in combination with chemotherapy showed encouraging safety and efficacy in patients with resectable NSCLC, thus warranting the ongoing phase 3 studies of neoadjuvant immunotherapy combined with chemotherapy. Preoperative and intraoperative unresectability after neoadjuvant ICIs appears comparable to that observed with neoadjuvant chemotherapy. To help thoracic surgeons and medical oncologists to distinguish among ICIs beyond efficacy as phase 3 data emerge, surgery-related end points for perioperative morbidity, mortality, and complexity should be defined, standardized, incorporated into trial designs, and reported.

The frontier of neoadjuvant therapy in non-small cell lung cancer beyond PD-(L)1 agents

Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives

Revamping Non-Small Cell Lung Cancer Treatments in Stages II and III: Preparing Healthcare for Cutting-Edge Immuno-Oncology Regimens

Advancing neoadjuvant therapies in resectable non-small cell lung cancer: implications for novel treatment strategies and biomarker discovery

The Earlier, the Better? A Review of Neoadjuvant Immunotherapy in Resectable Non‐small‐cell Lung Cancer

[Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer].

Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC

Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients with Early-Stage Non-small Cell Lung Cancer

Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art

Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives

Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon

Perioperative systemic therapies for non-small-cell lung cancer: Recent advances and future perspectives

Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review

Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?

Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges

Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer

The role of immunotherapy in early-stage and metastatic NSCLC

Adjuvant immunotherapy in early-stage resectable non–small cell lung cancer: A new milestone

The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer

Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives